Ian W. Flinn - Concepedia

Author

Ian W. Flinn

Sarah Cannon ORCID

Also Known As

Ai, Weiyun, Flinn, Ian, I Flinn, I W Flinn, I. Flinn, I. W. Flinn, I.W. Flinn, IW Flinn, Ian A Flinn, Ian Flinn

927

Publications

53.7K

Citations

H-Index

Concepts

All Affiliations

Sarah Cannon The University of Texas MD Anderson Cancer Center Tennessee Oncology The Ohio State University Cornell University

About

Ian W. Flinn is an author at Sarah Cannon specializing in oncology, medicine, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	36	101	9.8K
2	Health Sciences	24	46	3.6K
3	Engineering	2	2	48
4	Allergy	2	2	44
5	Biostatistics	1	1	30

Ian W. Flinn

391

Publications

51.6K

Citations

H-Index

Page 1

	Year	Citations
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, New England Journal of Medicine	2017	5.7K
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia John C. Byrd, Richard R. Furman, Steven Coutré, New England Journal of Medicine	2013	2.2K
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial Frederick L. Locke, Armin Ghobadi, Caron A. Jacobson, The Lancet Oncology Hematological MalignancyLymphoid NeoplasiaAxicabtagene CiloleucelMedicineImmunology	2018	2.2K
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma Michael Wang, Javier Muñoz, André Goy, New England Journal of Medicine	2020	1.7K
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia Richard R. Furman, Jeff P. Sharman, Steven Coutré, New England Journal of Medicine	2014	1.7K
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea, Blood	2017	1.4K
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma Frederick L. Locke, David B. Miklos, Caron A. Jacobson, New England Journal of Medicine	2021	1.4K
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma Ranjana H. Advani, Ian W. Flinn, Leslie Popplewell, New England Journal of Medicine	2018	1.1K
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma Ajay K. Gopal, Brad S. Kahl, Sven de Vos, New England Journal of Medicine	2014	1K
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study Michael J. Keating, Ian W. Flinn, Vinay Jain, Blood	2002	946

Page 1